| 证券代码：301017 | 证券简称：漱玉平民 | 公告编号：2025-102 | | --- | --- | --- | | 债券代码：123172 | 债券简称：漱玉转债 | | 漱玉平民大药房连锁股份有限公司 关于控股股东、实际控制人、董事长及其一致行动人 权益变动比例触及 1%整数倍暨减持计划实施完毕的公告 公司控股股东、实际控制人、董事长李文杰先生保证向本公司提供的信息内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈 述或者重大遗漏。 特别提示： 1、本次权益变动为控股股东、实际控制人、董事长李文杰先生实施之前披露的减持股 份计划导致的变动，不涉及要约收购。 2、自 2025 年 10 月 14 日至 2025 年 11 月 25 日，控股股东、实际控制人、董事长李文 杰先生通过大宗交易方式减持股份 6,047,200 股，占总股本比例 1.49%，占剔除回购后总股 本比例 1.50%。本次权益变动后，李文杰先生及其一致行动人济南漱玉锦云投资合伙企业（有 限合伙）（以下简称"漱玉锦云"）、济南漱玉通成投 ...

Market Overview - The pharmaceutical commercial sector increased by 1.34% compared to the previous trading day, with Huaren Health leading the gains [1] - The Shanghai Composite Index closed at 3864.18, down 0.15%, while the Shenzhen Component Index closed at 12907.83, up 1.02% [1] Stock Performance - Huaren Health (301408) saw a closing price of 17.40, with a significant increase of 20.00% and a trading volume of 345,500 shares, amounting to a transaction value of 570 million [1] - Other notable performers included: - Haiwang Biological (000078) with a closing price of 2.81, up 10.20% [1] - Renmin Tongtai (600829) at 13.18, up 10.02% [1] - Ruikang Pharmaceutical (002589) at 3.19, up 10.00% [1] - Yingte Group (000411) at 12.36, up 9.96% [1] Capital Flow - The pharmaceutical commercial sector experienced a net inflow of 665 million from main funds, while retail funds saw a net outflow of 366 million [2] - The main funds' net inflow for Huaren Health was 1.43 billion, representing 25.12% of the total, while retail funds had a net outflow of 596.87 million [3] - Other companies with significant main fund inflows included: - Ruikang Pharmaceutical with a net inflow of 118 million [3] - Renmin Tongtai with a net inflow of 115 million [3] - Haiwang Biological with a net inflow of 106 million [3]

（编辑 姚尧） 证券日报网讯 11月25日晚间，漱玉平民发布公告称，漱玉平民大药房连锁股份有限公司（以下简称"公 司"）于近日收到公司控股股东、实际控制人李文杰先生、持股5%以上股东秦光霞女士的通知，获悉其 所持有公司的部分股份办理了质押业务。本次质押股份数量为33，000，000股。 ...

| 交易日期 | 证券代码 | 证券简称 | 成交价格 | 成交量 | 成交金额 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | --- | | | | | (元) | (万股/万份) | (万元) | | | 2025-11-25 | 301017 | 激玉平民 | 10.44 | 204.72 | 2,137.2级城证券股份有限 | 光大证券股份有限 | | | | | | | 公司昆山登云路证 | 公司济南经十路证 | | | | | | | 劳营业部 | 劳营业部 | | 2025-11-25 | 301017 | 激玉平民 | 10.44 | 200.00 | 2,088. 级城证券股份有限 | 东兴证券股份有限 | | | | | | | 公司昆山登云路证 | 公司济南文化西路 | | | | | | | 券营业部 | 证券营业部 | 11月25日，漱玉平民大宗交易成交404.72万股，成交额4225.28万元，占当日总成交额的14.22%，成交 价10.44元，较市场收盘价13.79元折价24.29%。 ...

Core Viewpoint - The article highlights the rising demand for flu vaccines, antiviral medications, and related testing services due to the increasing flu activity across various regions in China as winter approaches [2][6][8]. Group 1: Flu Vaccine and Antiviral Demand - The flu season is expected to drive significant growth in demand for flu vaccines, respiratory testing, and antiviral medications [2][6]. - Recent data indicates a notable increase in flu vaccine appointments and antiviral drug purchases, with some areas reporting over 500% growth in the number of buyers for antiviral medications [7][8]. - Specific antiviral drugs like Marbofloxacin have seen a remarkable increase in demand, with purchases rising over 600% in recent weeks [7]. Group 2: Market Opportunities - Analysts suggest that the current flu outbreak may lead to heightened public and market interest, creating investment opportunities in flu vaccines, virus testing, and cold medications [8]. - The demand for flu-related products is expected to surge, particularly for antiviral medications such as Oseltamivir and Marbofloxacin, as well as traditional Chinese medicine for flu treatment [8]. - The increase in flu cases is likely to boost the need for diagnostic testing, both in hospitals and for home monitoring, indicating a potential market expansion for testing products [8].

| | | 漱玉平民大药房连锁股份有限公司 关于控股股东、实际控制人及持股 5%以上股东 部分股份质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 漱玉平民大药房连锁股份有限公司（以下简称"公司"）于近日收到公司控股股东、实 际控制人李文杰先生、持股 5%以上股东秦光霞女士的通知，获悉其所持有公司的部分股份 办理了质押业务，具体事项如下： 注：1、截至 2025 年 11 月 24 日，公司最新总股本为 405,355,636 股，本公告涉及计算相关股份数 量、比例时，以最新的总股本为准；上述限售股不包括高管锁定股。 一、股东股份质押基本情况 2、本次质押股份不存在负担重大资产重组等业绩补偿义务，以上数据差异均为四舍五入保留两位 小数所致。 （二）股东股份累计质押情况 公司控股股东李文杰先生与持股 5%以上股东济南漱玉锦云投资合伙企业（有限合伙） （以下简称"漱玉锦云"）、济南漱玉通成投资合伙企业（有限合伙）（以下简称"漱玉通成"） 为一致行动人。 截至公告披露日，控股股东李文杰先生及其一致行动人、持股 5%以上股东秦光霞女士 所持质押股份情况如下 ...

Core Viewpoint - The company, Shuyupingmin, announced that it and its subsidiaries have no overdue guarantees, no litigation-related guarantees, and are not liable for any losses due to guarantee-related judgments [2] Summary by Categories - **Company Financial Health** - Shuyupingmin confirmed that there are no overdue guarantees within the company and its consolidated subsidiaries [2] - The company stated that there are no litigation-related guarantees affecting its financial standing [2] - There are no circumstances where the company would incur losses due to guarantee-related judgments [2]

| | | 漱玉平民大药房连锁股份有限公司 关于为全资及控股子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、担保情况概述 漱玉平民大药房连锁股份有限公司（以下简称"公司"）于 2025 年 1 月 21 日召开第 四届董事会第三次会议，于 2025 年 2 月 6 日召开 2025 年第一次临时股东大会，审议通过 了《关于 2025 年度公司及子公司向银行等机构申请综合授信额度及提供担保的议案》，同 意公司及子公司 2025 年度对合并报表范围内各级子公司提供的担保额度为人民币 167,011.00 万元。其中公司向全资子公司东营益生堂药业连锁有限公司（以下简称"东营 益生堂"）提供不超过 15,500 万元的担保额度，向控股子公司漱玉医药物流（湖北）有限 公司（以下简称"湖北物流"）提供不超过 1,020 万元的担保额度。担保额度有效期自 2025 年第一次临时股东大会审议通过之日起十二个月。具体内容详见公司于 2025 年 1 月 22 日 和 2025 年 2 月 6 日分别在巨潮资讯网（www.cninfo.com.cn ...

11月21日，漱玉平民跌2.84%，成交额2.28亿元。两融数据显示，当日漱玉平民获融资买入额1559.09万 元，融资偿还1700.37万元，融资净买入-141.28万元。截至11月21日，漱玉平民融资融券余额合计 8035.09万元。 截至9月30日，漱玉平民股东户数1.31万，较上期减少7.43%；人均流通股18643股，较上期增加8.02%。 2025年1月-9月，漱玉平民实现营业收入74.46亿元，同比增长5.19%；归母净利润1.09亿元，同比增长 927.37%。 分红方面，漱玉平民A股上市后累计派现1.41亿元。近三年，累计派现6673.17万元。 机构持仓方面，截止2025年9月30日，漱玉平民十大流通股东中，香港中央结算有限公司位居第九大流 通股东，持股78.60万股，相比上期减少47.65万股。 责任编辑：小浪快报 融资方面，漱玉平民当日融资买入1559.09万元。当前融资余额8035.09万元，占流通市值的1.52%，融 资余额超过近一年90%分位水平，处于高位。 融券方面，漱玉平民11月21日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量0. ...

Market Overview - The pharmaceutical commercial sector experienced a decline of 0.51% on November 20, with Renmin Tongtai leading the drop [1] - The Shanghai Composite Index closed at 3931.05, down 0.4%, while the Shenzhen Component Index closed at 12980.82, down 0.76% [1] Stock Performance - Notable gainers included: - HeFu China (603122) with a closing price of 26.18, up 10.00% [1] - KaiKai Industry (600272) at 14.58, up 4.14% [1] - Zhejiang Zhenyuan (000705) at 9.91, up 1.64% [1] - Major decliners included: - Renmin Tongtai (600829) at 14.36, down 9.97% [2] - Jianfa Zhixin (301584) at 32.34, down 4.88% [2] - Shuyupingmin (301017) at 13.40, down 3.11% [2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 260 million yuan from institutional investors, while retail investors had a net inflow of 264 million yuan [2] - The overall capital flow indicates a shift in investor sentiment, with retail investors showing more interest in the sector [2] Individual Stock Capital Flow - Shanghai Pharmaceuticals (601607) had a net inflow of 36.98 million yuan from institutional investors, but a net outflow from retail investors [3] - KaiKai Industry (600272) also saw a net inflow from institutional investors of 27.76 million yuan, with retail investors showing a net outflow [3] - Other stocks like Zhejiang Zhenyuan (000705) and Dajia Weikang (301126) experienced mixed capital flows, indicating varied investor interest [3]